TauroLock™ in small children: effective, safe and cost-efficient
Effects of prophylactic use of taurolidine-citrate lock on the number of catheter-related infections in children under 2 years of age undergoing surgery.
Łyszkowska M, Kowalewski G, Szymczak M, Polnik D, Mikołajczyk A, Kaliciński P. J Hosp Infect. 2019 Oct;103(2):223-226. doi: 10.1016/j.jhin.2019.04.022.
The authors performed a randomised study in children (< 2 years of age) undergoing surgery. CVCs were mainly inserted for parenteral nutrition but also for the supply of drugs and blood products.
TauroLock™ was very successfully used for the prevention of catheter-related infections. We want to stress that the authors report no adverse events even in these very young children.
86 children (97 catheters) undergoing surgery, CVCs were inserted for PN (mainly) or supply of drugs and blood products. CVCs were randomised to either standard aseptic procedures and locked with TauroLock™ (TauroLock™-group) or to standard aseptic procedures and locked with saline (saline-group). TauroLock™ dwell time was at least 2 hours (2 to 24 hours/day), depending on when CVCs were used next.
- Catheter-related infections (CABSI)
Significantly lower CABSI rate in the TauroLock™-group vs. saline-group (1.06 infections per 1000 catheter days vs. 14.3, p<0.05) .
(Attention: in the publication CABSI is referred to as CRI)
- CVC related costs:
Immense cost savings were calculated when CVCs were blocked with TauroLock™. The average cost of treatment resulting from one CABSI was 3.304 €. With 16 CABSI in the saline-group and 1 in the TauroLock™-group the catheter related costs, including costs for lock solution, treatment of infections etc. were 52.864 € in the saline-group and 8.163 € in the TauroLock™-group.
No adverse events were reported.
Use of TauroLock™ appears to be a safe and effective method of preventing CRI in very young children, and is associated with immense cost-savings.